News

Hugh and his fellow cyclists covered 62-miles and stopped at all 12 London football league grounds to support our work.

We are so grateful to everyone who has already donated to our 2020 Emergency Appeal.

Our team have recorded a special thank you for this vital support at such a challenging time.

Tafasitamab plus lenalidomide show promise for people with relapsed or refractory DLBCL who are not suitable for a stem cell transplant.

Possible questions to ask if you are returning to work after shielding. 

Brentuximab vedotin is to be available on the NHS for first-line treatment of anaplastic large cell lymphoma.

Selinexor shows early potential for people with relapsed or refractory DLBCL who have had at least two previous courses of treatment.

How strong is the evidence that Roundup® contributes to the development of non-Hodgkin lymphoma?

We have united with 24 other cancer charities to develop a 12-point plan for restoring cancer services.

The American Society of Clinical Oncology (ASCO) held a virtual conference at the end of May.

Acalabrutinib shows potential as a chemotherapy-free treatment option for people with CLL who have not been treated before.